SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Falk Nimmerjahn, Sina Gordan, Anja Lux, FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities, Trends in Immunology, 2015, 36, 6, 325

    CrossRef

  2. 2
    Shambhavi Naik, Marion MacFarlane, Apurva Sarin, Notch4 Signaling Confers Susceptibility to TRAIL-Induced Apoptosis in Breast Cancer Cells, Journal of Cellular Biochemistry, 2015, 116, 7
  3. 3
    H Wajant, Principles of antibody-mediated TNF receptor activation, Cell Death and Differentiation, 2015, 22, 11, 1727

    CrossRef

  4. 4
    Andrea Mohr, Rui Yu, Ralf M. Zwacka, TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill, BMC Cancer, 2015, 15, 1

    CrossRef

  5. 5
    J Trebing, M El-Mesery, V Schäfer, D Weisenberger, D Siegmund, K Silence, H Wajant, CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants, Cell Death and Disease, 2014, 5, 1, e1035

    CrossRef

  6. 6
    Heather A Huet, Joseph D Growney, Jennifer A Johnson, Jing Li, Sanela Bilic, Lance Ostrom, Mohammad Zafari, Colleen Kowal, Guizhi Yang, Axelle Royo, Michael Jensen, Bruno Dombrecht, Kris RA Meerschaert, Joost A Kolkman, Karen D Cromie, Rebecca Mosher, Hui Gao, Alwin Schuller, Randi Isaacs, William R Sellers, Seth A Ettenberg, Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction, mAbs, 2014, 6, 6, 1560

    CrossRef

  7. 7
    Denise Alves Perez, Juliana Priscila Vago, Rayssa Maciel Athayde, Alesandra Corte Reis, Mauro Martins Teixeira, Lirlândia Pires Sousa, Vanessa Pinho, Switching Off Key Signaling Survival Molecules to Switch On the Resolution of Inflammation, Mediators of Inflammation, 2014, 2014, 1

    CrossRef

  8. 8
    Ingrid A.M. van Roosmalen, Wim J. Quax, Frank A.E. Kruyt, Two death-inducing human TRAIL receptors to target in cancer: Similar or distinct regulation and function?, Biochemical Pharmacology, 2014, 91, 4, 447

    CrossRef

  9. 9
    Marco de Bruyn, Edwin Bremer, Wijnand Helfrich, Antibody-based fusion proteins to target death receptors in cancer, Cancer Letters, 2013, 332, 2, 175

    CrossRef

  10. 10
    M El-Mesery, J Trebing, V Schäfer, D Weisenberger, D Siegmund, H Wajant, CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells, Cell Death and Disease, 2013, 4, 11, e916

    CrossRef

  11. You have free access to this content11
    O Micheau, S Shirley, F Dufour, Death receptors as targets in cancer, British Journal of Pharmacology, 2013, 169, 8
  12. 12
    Tadeusz Robak, Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia, Future Oncology, 2013, 9, 1, 69

    CrossRef

  13. 13
    L Y Dimberg, C K Anderson, R Camidge, K Behbakht, A Thorburn, H L Ford, On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics, Oncogene, 2013, 32, 11, 1341

    CrossRef

  14. 14
    Martin J. S. Dyer, Meike Vogler, Jesvin Samuel, Sandrine Jayne, Simon Wagner, Catrin Pritchard, Salvador Macip, Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls, British Journal of Haematology, 2013, 160, 6
  15. 15
    Zhigang Kang, Shi-Yong Sun, Liang Cao, Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma, ISRN Oncology, 2012, 2012, 1

    CrossRef

  16. 16
    Marie P. Piechocki, Gen Sheng Wu, Richard F. Jones, Jennifer B. Jacob, Heather Gibson, Stephen P. Ethier, Judith Abrams, Hideo Yagita, K Venuprasad, Wei-Zen Wei, Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA, International Journal of Cancer, 2012, 131, 11
  17. 17
    Laura S. Dickens, Ian R. Powley, Michelle A. Hughes, Marion MacFarlane, The ‘complexities’ of life and death: Death receptor signalling platforms, Experimental Cell Research, 2012, 318, 11, 1269

    CrossRef

  18. 18
    Nicholas S. Wilson, Becky Yang, Annie Yang, Stefanie Loeser, Scot Marsters, David Lawrence, Yun Li, Robert Pitti, Klara Totpal, Sharon Yee, Sarajane Ross, Jean-Michel Vernes, Yanmei Lu, Cam Adams, Rienk Offringa, Bob Kelley, Sarah Hymowitz, Dylan Daniel, Gloria Meng, Avi Ashkenazi, An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells, Cancer Cell, 2011, 19, 1, 101

    CrossRef

  19. 19
    Giorgio Zauli, Raffaella Bosco, Paola Secchiero, Molecular targets for selective killing of TRAIL-resistant leukemic cells, Expert Opinion on Therapeutic Targets, 2011, 15, 8, 931

    CrossRef

  20. 20
    Lukas P. Frenzel, Michaela Patz, Christian P. Pallasch, Reinhild Brinker, Julia Claasen, Alexandra Schulz, Michael Hallek, Hamid Kashkar, Clemens-Martin Wendtner, Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis, British Journal of Haematology, 2011, 152, 2
  21. 21
    Jian Chen, Xiaobai Sun, Weihua Yang, Guosheng Jiang, Xingang Li, Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro, Tumor Biology, 2010, 31, 6, 613

    CrossRef

  22. 22
    Seung-Hyun Lee, Dong-Woon Park, Eun-Sil Sung, Hye-Ran Park, Jin-Kyoo Kim, Yong-Sung Kim, Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity, Molecular Immunology, 2010, 47, 4, 816

    CrossRef

  23. 23
    Junaid Abdulghani, Wafik S El-Deiry, TRAIL receptor signaling and therapeutics, Expert Opinion on Therapeutic Targets, 2010, 14, 10, 1091

    CrossRef

  24. 24
    Simone Fulda, Cell death in hematological tumors, Apoptosis, 2009, 14, 4, 409

    CrossRef

  25. 25
    M. MacFarlane, Cell death pathways – potential therapeutic targets, Xenobiotica, 2009, 39, 8, 616

    CrossRef

  26. 26
    Thomas Newsom-Davis, Silvia Prieske, Henning Walczak, Is TRAIL the holy grail of cancer therapy?, Apoptosis, 2009, 14, 4, 607

    CrossRef

  27. 27
    Daniela Berg, Thorsten Stühmer, Daniela Siegmund, Nicole Müller, Tina Giner, Oliver Dittrich-Breiholz, Michael Kracht, Ralf Bargou, Harald Wajant, Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways, The FEBS Journal, 2009, 276, 23
  28. 28
    Xiao-Ming Sun, Ana Canda-Sánchez, Ganesh R. Manjeri, Gerald M. Cohen, Michael J. Pinkoski, Phenylarsine oxide interferes with the death inducing signaling complex and inhibits tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis, Experimental Cell Research, 2009, 315, 14, 2453

    CrossRef

  29. 29
    Tom M. Ganten, Jaromir Sykora, Ronald Koschny, Emanuela Batke, Sebastian Aulmann, Ulrich Mansmann, Wolfgang Stremmel, Hans-Peter Sinn, Henning Walczak, Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer, Journal of Molecular Medicine, 2009, 87, 10, 995

    CrossRef

  30. 30
    Kerstin Papenfuss, Stefanie M. Cordier, Henning Walczak, Death receptors as targets for anti-cancer therapy, Journal of Cellular and Molecular Medicine, 2008, 12, 6b
  31. 31
    Jing Li, Deborah A. Knee, Youzhen Wang, Qingxiu Zhang, Jennifer A. Johnson, Jane Cheng, Helen He, Christine Miller, Zhifang Li, Colleen Kowal, Joseph Eckman, Betty Tang, Jing Yuan, Liqing Chen, Quinn Deveraux, Marc S. Nasoff, David Stover, LBY135, a novel anti-DR5 agonistic antibody induces tumor cell–specific cytotoxic activity in human colon tumor cell lines and xenografts, Drug Development Research, 2008, 69, 2
  32. 32
    P Geserick, C Drewniok, M Hupe, T L Haas, P Diessenbacher, M R Sprick, M P Schön, F Henkler, H Gollnick, H Walczak, M Leverkus, Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis, Oncogene, 2008, 27, 22, 3211

    CrossRef

  33. 33
    Marion MacFarlane, Death Receptors at the Molecular Level: Therapeutic Implications, eLS,